Switch theme
Sign up to access all valuation multiples
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
2019
134
LTM Revenue $85.0M
LTM EBITDA -$95.9M
-$25.9M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Monte Rosa Therapeutics has a last 12-month revenue (LTM) of $85.0M and a last 12-month EBITDA of -$95.9M.
In the most recent fiscal year, Monte Rosa Therapeutics achieved revenue of $75.6M and an EBITDA of -$73.0M.
Monte Rosa Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Monte Rosa Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $85.0M | XXX | $75.6M | XXX | XXX | XXX |
| Gross Profit | $82.5M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 97% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$95.9M | XXX | -$73.0M | XXX | XXX | XXX |
| EBITDA Margin | -113% | XXX | -97% | XXX | XXX | XXX |
| EBIT | -$77.8M | XXX | -$81.1M | XXX | XXX | XXX |
| EBIT Margin | -91% | XXX | -107% | XXX | XXX | XXX |
| Net Profit | -$68.3M | XXX | -$72.7M | XXX | XXX | XXX |
| Net Margin | -80% | XXX | -96% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Monte Rosa Therapeutics's stock price is $4.
Monte Rosa Therapeutics has current market cap of $258M, and EV of -$25.9M.
See Monte Rosa Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$25.9M | $258M | XXX | XXX | XXX | XXX | $-0.90 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Monte Rosa Therapeutics has market cap of $258M and EV of -$25.9M.
Monte Rosa Therapeutics's trades at -0.3x EV/Revenue multiple, and 0.4x EV/EBITDA.
Equity research analysts estimate Monte Rosa Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Monte Rosa Therapeutics has a P/E ratio of -3.8x.
See valuation multiples for Monte Rosa Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $258M | XXX | $258M | XXX | XXX | XXX |
| EV (current) | -$25.9M | XXX | -$25.9M | XXX | XXX | XXX |
| EV/Revenue | -0.3x | XXX | -0.3x | XXX | XXX | XXX |
| EV/EBITDA | 0.3x | XXX | 0.4x | XXX | XXX | XXX |
| EV/EBIT | 0.3x | XXX | 0.3x | XXX | XXX | XXX |
| EV/Gross Profit | -0.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | -3.8x | XXX | -3.6x | XXX | XXX | XXX |
| EV/FCF | -6.6x | XXX | -0.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMonte Rosa Therapeutics's last 12 month revenue growth is -13%
Monte Rosa Therapeutics's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $1.2M for the same period.
Monte Rosa Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Monte Rosa Therapeutics's rule of X is -144% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Monte Rosa Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -13% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -113% | XXX | -97% | XXX | XXX | XXX |
| EBITDA Growth | 18% | XXX | -8% | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | -109% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -144% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 161% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 207% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Monte Rosa Therapeutics acquired XXX companies to date.
Last acquisition by Monte Rosa Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Monte Rosa Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Monte Rosa Therapeutics founded? | Monte Rosa Therapeutics was founded in 2019. |
| Where is Monte Rosa Therapeutics headquartered? | Monte Rosa Therapeutics is headquartered in United States of America. |
| How many employees does Monte Rosa Therapeutics have? | As of today, Monte Rosa Therapeutics has 134 employees. |
| Who is the CEO of Monte Rosa Therapeutics? | Monte Rosa Therapeutics's CEO is Dr. Markus Warmuth, M.D.. |
| Is Monte Rosa Therapeutics publicy listed? | Yes, Monte Rosa Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Monte Rosa Therapeutics? | Monte Rosa Therapeutics trades under GLUE ticker. |
| When did Monte Rosa Therapeutics go public? | Monte Rosa Therapeutics went public in 2021. |
| Who are competitors of Monte Rosa Therapeutics? | Similar companies to Monte Rosa Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Monte Rosa Therapeutics? | Monte Rosa Therapeutics's current market cap is $258M |
| What is the current revenue of Monte Rosa Therapeutics? | Monte Rosa Therapeutics's last 12 months revenue is $85.0M. |
| What is the current revenue growth of Monte Rosa Therapeutics? | Monte Rosa Therapeutics revenue growth (NTM/LTM) is -13%. |
| What is the current EV/Revenue multiple of Monte Rosa Therapeutics? | Current revenue multiple of Monte Rosa Therapeutics is -0.3x. |
| Is Monte Rosa Therapeutics profitable? | Yes, Monte Rosa Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Monte Rosa Therapeutics? | Monte Rosa Therapeutics's last 12 months EBITDA is -$95.9M. |
| What is Monte Rosa Therapeutics's EBITDA margin? | Monte Rosa Therapeutics's last 12 months EBITDA margin is -113%. |
| What is the current EV/EBITDA multiple of Monte Rosa Therapeutics? | Current EBITDA multiple of Monte Rosa Therapeutics is 0.3x. |
| What is the current FCF of Monte Rosa Therapeutics? | Monte Rosa Therapeutics's last 12 months FCF is $3.9M. |
| What is Monte Rosa Therapeutics's FCF margin? | Monte Rosa Therapeutics's last 12 months FCF margin is 5%. |
| What is the current EV/FCF multiple of Monte Rosa Therapeutics? | Current FCF multiple of Monte Rosa Therapeutics is -6.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
